APA (7th ed.) Citation

Company Pfizer. (2019). According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention. Столичная издательская компания.

Chicago Style (17th ed.) Citation

Company Pfizer. According to the AUGUSTUS Trial Apixaban (Eliquis ® ) Was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome And/or Percutaneous Coronary Intervention. Столичная издательская компания, 2019.

MLA (9th ed.) Citation

Company Pfizer. According to the AUGUSTUS Trial Apixaban (Eliquis ® ) Was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome And/or Percutaneous Coronary Intervention. Столичная издательская компания, 2019.